Antonia Potarca

1.3k total citations · 1 hit paper
16 papers, 919 citations indexed

About

Antonia Potarca is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Immunology. According to data from OpenAlex, Antonia Potarca has authored 16 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 7 papers in Genetics and 6 papers in Immunology. Recurrent topics in Antonia Potarca's work include Vasculitis and related conditions (8 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers) and Immune cells in cancer (4 papers). Antonia Potarca is often cited by papers focused on Vasculitis and related conditions (8 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers) and Immune cells in cancer (4 papers). Antonia Potarca collaborates with scholars based in United States, Netherlands and United Kingdom. Antonia Potarca's co-authors include Pirow Bekker, Thomas J. Schall, Vladimı́r Tesař, Annette Bruchfeld, David Jayne, Matthias Schaier, Michael Venning, Mårten Segelmark, Michel Jadoul and Lorraine Harper and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American Society of Nephrology and Annals of the Rheumatic Diseases.

In The Last Decade

Antonia Potarca

16 papers receiving 905 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

2017 420 citations David Jayne, Annette Bruchfeld et al. Journal of the American Society of Nephrology profile →

Peers

Countries citing papers authored by Antonia Potarca

Since Specialization

Citations

This map shows the geographic impact of Antonia Potarca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonia Potarca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonia Potarca more than expected).

Fields of papers citing papers by Antonia Potarca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonia Potarca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonia Potarca. The network helps show where Antonia Potarca may publish in the future.

Co-authorship network of co-authors of Antonia Potarca

This figure shows the co-authorship network connecting the top 25 collaborators of Antonia Potarca. A scholar is included among the top collaborators of Antonia Potarca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonia Potarca. Antonia Potarca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study 2021 ·Clinical Kidney Journal ·Annette Bruchfeld, (unknown), Patrick H. Nachman, Samir M. Parikh, Richard Lafayette, Antonia Potarca, Shichang Miao, Pirow Bekker	57
2	Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis 2020 ·ACR Open Rheumatology ·Peter A. Merkel, John L. Niles, (unknown), Robert Spiera, Brad H. Rovin, Andrew S. Bomback, Christian Pagnoux, Antonia Potarca, Thomas J. Schall, Pirow Bekker, (unknown)	81
3	326. A RANDOMIZED PHASE 3 TRIAL EVALUATING THE SAFETY AND EFFICACY OF AVACOPAN IN PATIENTS WITH NEW OR RELAPSING ANCA-ASSOCIATED VASCULITIS 2019 ·Lara D. Veeken ·Peter A. Merkel, David Jayne, Masayoshi Harigai, Thomas J. Schall, Pirow Bekker, Antonia Potarca, Jan Hillson	1
4	FP167ADVERSE EVENTS WITH GLUCOCORTICOID STANDARD OF CARE VERSUS AVACOPAN IN ANCA-ASSOCIATED VASCULITIS: OBSERVATIONS FROM THE CLEAR TRIAL 2018 ·Nephrology Dialysis Transplantation ·David Jayne, Antonia Potarca, Thomas J. Schall, (unknown), (unknown)	2
5	Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts. 2018 ·Journal of Clinical Oncology ·David C. Linehan, Marcus Smith Noel, Aram F. Hezel, Andrea Wang‐Gillam, Ferry A.L.M. Eskens, Stefan Sleijfer, Ingrid M.E. Desar, Frans Erdkamp, Johanna W. Wilmink, J. Nathaniel Diehl, Antonia Potarca, (unknown), Shichang Miao, Jun Deng, Jan Hillson, Pirow Bekker, Thomas J. Schall, Rajinder Singh	77
6	Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis breakdown → 2017 ·Journal of the American Society of Nephrology ·David Jayne, Annette Bruchfeld, Lorraine Harper, Matthias Schaier, Michael Venning, Patrick Hamilton, Volker Burst, Franziska Grundmann, Michel Jadoul, István Szombati, Vladimı́r Tesař, Mårten Segelmark, Antonia Potarca, Thomas J. Schall, Pirow Bekker, (unknown)	420
7	Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer. 2017 ·Journal of Clinical Oncology ·Marcus Smith Noel, Aram F. Hezel, David C. Linehan, Andrea Wang‐Gillam, Ferry A.L.M. Eskens, Stefan Sleijfer, Ingrid M.E. Desar, Frans Erdkamp, Johanna W. Wilmink, J. Nathaniel Diehl, Antonia Potarca, (unknown), Jun Deng, Lisa Lohr, Shichang Miao, Israel Charo, Rajinder Singh, Thomas J. Schall, Pirow Bekker	27
8	TO012C5A RECEPTOR INHIBITOR AVACOPAN IN IGA NEPHROPATHY STUDY 2017 ·Nephrology Dialysis Transplantation ·Annette Bruchfeld, Patrick H. Nachman, Samir V. Parikh, Richard Lafayette, Antonia Potarca, J. Nathaniel Diehl, Lisa Lohr, Shichang Miao, Thomas J. Schall, Pirow Bekker	11
9	MO039SUCCESSFUL STEROID REPLACEMENT IN ANCA-ASSOCIATED VASCULITIS WITH C5A RECEPTOR INHIBITOR CCX168 IN PHASE 2 RANDOMISED TRIAL (CLEAR) 2016 ·Nephrology Dialysis Transplantation ·David Jayne, Annette Bruchfeld, Lorraine Harper, Matthias Schaier, Michael Venning, (unknown), Volker Burst, (unknown), Michel Jadoul, István Szombati, Vladimı́r Tesař, Mårten Segelmark, Antonia Potarca, Thomas J. Schall, Pirow Bekker	2
10	The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients. 2016 ·Journal of Clinical Oncology ·Andrea Wang‐Gillam, Marcus Smith Noel, Stefan Sleijfer, Heiyoun Jung, Lisa Lohr, (unknown), Shichang Miao, Antonia Potarca, Israel Charo, (unknown), Thomas J. Schall	1
11	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial 2015 ·The Lancet Diabetes & Endocrinology ·Dick de Zeeuw, Pirow Bekker, Elena Henkel, (unknown), Ioanna Gouni-Berthold, Heidrun Mehling, Antonia Potarca, Vladimı́r Tesař, Hiddo J.L. Heerspink, Thomas J. Schall	220
12	Abstract B24: Pharmacokinetic and pharmacodynamic profile of the novel, oral and selective CCR2 inhibitor CCX872-B in a Phase 1B pancreatic cancer trial 2015 ·Molecular Cancer Therapeutics ·Aram F. Hezel, Ferry A.L.M. Eskens, Stefan Sleijfer, Marcus Smith Noel, Andrea Wang‐Gillam, (unknown), Antonia Potarca, Bin Zhao, Lisa Lohr, Shichang Miao, Israel Charo, Pirow Bekker, Thomas J. Schall	1
13	SP457CCR2 INHIBITOR CCX140 EFFECTIVE IN PHASE 2 CLINICAL TRIAL IN DIABETIC NEPHROPATHY 2015 ·Nephrology Dialysis Transplantation ·Dick de Zeeuw, Elena Henkel, (unknown), György Paragh, Heidrun Mehling, (unknown), Antonia Potarca, Pirow Bekker, Thomas J. Schall	2
14	Phase 2 randomised trial of oral C5A receptor antagonist CCX168 in ANCA-associated renal vasculitis 2014 ·Nephrology Dialysis Transplantation ·David Jayne, Annette Bruchfeld, Matthias Schaier, Kazimierz Ciechanowski, Lorraine Harper, Michel Jadoul, Mårten Segelmark, Daina Selga, István Szombati, Michael Venning, (unknown), Christian Hugo, Paul Van Daele, Ondřej Viklický, Antonia Potarca, Thomas J. Schall, Pirow Bekker	4
15	OP0227 Oral C5a Receptor Antagonist CCX168 Phase 2 Clinical TRIAL in Anca-Associated Renal Vasculitis 2014 ·Annals of the Rheumatic Diseases ·David Jayne, Annette Bruchfeld, Matthias Schaier, Kazimierz Ciechanowski, Lorraine Harper, Michel Jadoul, Mårten Segelmark, Daina Selga, István Szombati, Mike Venning, Christian Hugo, Paul Van Daele, Ondřej Viklický, Antonia Potarca, Thomas J. Schall, Pirow Bekker	12
16	Phase 2 clinical trial of CCX168, an orally administered C5aR antagonist, in patients with ANCA-associated renal vasculitis (CLEAR) 2013 ·Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) ·Annette Bruchfeld, Matthias Schaier, Lorraine Harper, Michel Jadoul, Mårten Segelmark, István Szombati, Michael Venning, Patrick Hamilton, Christian Hugo, Paul Van Daele, Ondřej Viklický, David Jayne, Antonia Potarca, Juan C. Jaén, Thomas J. Schall, Pirow Bekker	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact